These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39047884)

  • 1. Circulating tumor DNA in Egyptian women with breast Cancer: A marker for detection of primary cases and early prediction of recurrence.
    Gameel AM; Talaat RM; Sakr MA; Selim MA; Abo Alil DFA; Elkhouly EA
    Clin Chim Acta; 2024 Aug; 562():119878. PubMed ID: 39047884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
    Hussein NA; Mohamed SN; Ahmed MA
    Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
    Chen C; Chen Q; Dong Y; Liu X
    Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
    Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
    Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
    Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
    Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
    Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer.
    Stötzer OJ; Lehner J; Fersching-Gierlich D; Nagel D; Holdenrieder S
    Tumour Biol; 2014 Feb; 35(2):1183-91. PubMed ID: 24018822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
    Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
    Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
    [No Abstract]   [Full Text] [Related]  

  • 13. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
    Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
    Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
    Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
    Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of serum microRNA-21 and miRNA-205 as diagnostic markers for stage I and II breast cancer in Indian population.
    Rama K; Bitla AR; Hulikal N; Yootla M; Yadagiri LA; Asha T; Manickavasagam M; Srinivasa Rao P
    Indian J Cancer; 2024 Apr; 61(2):290-298. PubMed ID: 38090957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.